SCHEMBL15568816

SCHEMBL15568816

CNC(=O)c1ccc(-c2ccc([C@@]3(NC(=O)c4ccc(F)cc4)CCOc4cccnc43)cc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 1/20 0.52
CYP2C8 P10632 6/20 0.40
CYP3A4 P08684 5/20 0.40
KCNH2 Q12809 3/20 0.40
NR1I2 O75469 1/20 0.38
MKNK1 Q9BUB5 1/20 0.38
MKNK2 Q9HBH9 1/20 0.38
RIPK1 Q13546 1/20 0.36
PLD2 O14939 1/20 0.35
PLD1 Q13393 1/20 0.35
PIK3CD O00329 1/20 0.35
PIK3CA P42336 1/20 0.35
MTOR P42345 1/20 0.35
SCD5 Q86SK9 1/20 0.35
IDO1 P14902 2/20 0.35
RAB9A P51151 2/20 0.35
CYP2D6 P10635 1/20 0.34
OPRD1 P41143 1/20 0.34
OPRK1 P41145 1/20 0.34
NPY5R Q15761 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15568817 1.00 TRPM8 (0.52) TRPM8CYP2C8CYP3A4KCNH2NR1I2
SCHEMBL16413960 0.95 TRPM8 (0.56) TRPM8CYP2C8CYP3A4KCNH2PLD2
SCHEMBL16413959 0.95 TRPM8 (0.56) TRPM8CYP2C8CYP3A4KCNH2PLD2
SCHEMBL16413757 0.92 TRPM8 (0.53) TRPM8CYP2C8CYP3A4KCNH2NR1I2
SCHEMBL16413753 0.92 TRPM8 (0.53) TRPM8CYP2C8CYP3A4KCNH2NR1I2
SCHEMBL15567528 0.92 TRPM8 (0.53) TRPM8CYP2C8CYP3A4KCNH2NR1I2
SCHEMBL16418690 0.92 TRPM8 (0.51) TRPM8CYP2C8CYP3A4KCNH2NR1I2
SCHEMBL15567178 0.91 TRPM8 (0.53) TRPM8CYP2C8CYP3A4PLD2PLD1
SCHEMBL15567181 0.91 TRPM8 (0.53) TRPM8CYP2C8CYP3A4PLD2PLD1
SCHEMBL16413930 0.91 TRPM8 (0.52) TRPM8CYP2C8CYP3A4KCNH2PLD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC (US) 2015-01-29 US claimed
WO-2014025651-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 WO claimed
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC (US) 2015-01-29 US disclosed
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC (US) 2015-01-29 US disclosed
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC (US) 2015-01-29 US disclosed
WO-2014025651-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS TRPM8, TRPM5, TRPM7 TRPM8 1/4885CYP2C8 32/4885CYP3A4 1842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.